CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
The Role of Exercise in Memory Function , homeMay 23, 2025, 11:00 a.m. | Henriette van Praag, Ph.D., Associate Professor, Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University | Co-Sponsored by the Center for Exercise Medicine Research, Fralin Biomedical Research Institute
-
Home Item
Pathways and Regulation of Cardiac Nav1.5 Channel Trafficking in Adult Myocytes , homeMay 30, 2025, 11:00 a.m. | Gea-Ny Tseng, Ph.D., Professor, Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home Item
Targeting Acquired Dependencies During Tumor Evolution , homeJune 6, 2025, 11:00 a.m. | Kris Wood, Ph.D., Associate Professor, Department of Pharmacology and Cancer Biology, Duke University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – D.C.